amifostine anhydrous has been researched along with Dysmyelopoietic Syndromes in 35 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two patients had RAEB, four RA and one RARS." | 2.70 | Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes. ( Bourantas, KL; Christou, L; Kapsali, HD; Panteli, K; Tsiara, SN, 2001) |
| " We have treated 10 patients with 250 mg/m2 amifostine thrice weekly in combination with erythropoietin for 4 consecutive weeks followed by 2 weeks observation." | 2.70 | Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodysplastic syndrome. ( Eibl, M; Jaeger, G; Linkesch, W; Neumeister, P; Sormann, S; Zinke, W, 2001) |
| " Administration formula was as follows: the intravenous drip of amifostine at a dosage of 0." | 1.35 | [Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome]. ( Fan, H; Li, SX; Liu, Y; Lu, XC; Yang, B; Yao, SQ; Zhu, HL, 2009) |
| "The aim of this study was to investigate the curative effect of amifostine (AMF) combined with recombinant human erythropoietin (rhEPO) on the aged patients with myelodysplastic syndrome." | 1.33 | [Short-term curative effect of amifostine combined with rhEPO on aged patients wilh myelodysplastic syndrome]. ( Fan, H; Lu, XC; Yang, Y; Yao, SQ; Zhu, HL; Zhuang, XM, 2005) |
| "Ten anemic patients with favorable myelodysplastic syndrome (MDS) were first treated with two 5-week courses of amifostine alone (each course consisted of 200 mg/m(2) of the drug given intravenously three times a week for 3 weeks), followed by an additional two courses combined with subcutaneous erythropoietin (EPO) (150 U/kg, three times a week for 8 weeks)." | 1.31 | Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. ( Dispenzieria, A; Elliott, MA; Hanson, CA; Hook, CC; Letendre, L; Schroeder, G; Steensma, DP; Tefferi, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (17.14) | 18.2507 |
| 2000's | 26 (74.29) | 29.6817 |
| 2010's | 3 (8.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, B | 3 |
| Wang, HT | 1 |
| Cai, LL | 2 |
| Zhao, Y | 1 |
| Chi, XH | 1 |
| Zhu, HL | 5 |
| Ran, HH | 1 |
| Yang, Y | 3 |
| Yu, RL | 1 |
| Li, SW | 1 |
| Lu, XC | 4 |
| Erikci, AA | 1 |
| Ozturk, A | 1 |
| Karagoz, B | 1 |
| Bilgi, O | 1 |
| Turken, O | 1 |
| Top, C | 1 |
| Kandemir, EG | 1 |
| Schanz, J | 1 |
| Jung, H | 1 |
| Wörmann, B | 2 |
| Gassmann, W | 1 |
| Petersen, T | 1 |
| Hinke, A | 1 |
| Haase, D | 2 |
| Fan, H | 3 |
| Li, SX | 2 |
| Liu, Y | 1 |
| Yao, SQ | 3 |
| Dang, YH | 1 |
| Li, W | 1 |
| Huang, Y | 1 |
| Mathew, P | 1 |
| Gerbing, R | 1 |
| Alonzo, TA | 1 |
| Wallas, T | 1 |
| Gong, JZ | 1 |
| Jasty, R | 1 |
| Jorstad, DT | 1 |
| Raimondi, SC | 1 |
| Chavez, CM | 1 |
| Eisenberg, NL | 1 |
| Hirsch, B | 1 |
| Gamis, A | 1 |
| Smith, FO | 1 |
| Arceci, RJ | 1 |
| Ravindranath, Y | 1 |
| Delforge, M | 1 |
| Raets, V | 1 |
| Van Duppen, V | 1 |
| Boogaerts, M | 1 |
| Musch, E | 1 |
| Malek, M | 1 |
| Chrissafidou, A | 1 |
| Benesch, M | 1 |
| McDonald, GB | 1 |
| Schubert, M | 1 |
| Appelbaum, FR | 1 |
| Deeg, HJ | 1 |
| Zhuang, XM | 2 |
| Akel, SM | 1 |
| Atoum, MF | 1 |
| Saleh, SA | 1 |
| Awadallah, SM | 1 |
| Naing, A | 1 |
| Sokol, L | 1 |
| List, AF | 5 |
| Qian, HL | 1 |
| Shen, ZJ | 1 |
| Hu, XD | 1 |
| Hu, YX | 1 |
| Yu, K | 1 |
| Ma, J | 1 |
| Yang, QM | 1 |
| Brasfield, F | 1 |
| Heaton, R | 1 |
| Glinsmann-Gibson, B | 1 |
| Crook, L | 1 |
| Taetle, R | 1 |
| Capizzi, R | 1 |
| Santini, V | 3 |
| Ferrini, PR | 1 |
| Bowen, DT | 2 |
| Denzlinger, C | 1 |
| Brugger, W | 1 |
| Culligan, D | 1 |
| Gelly, K | 1 |
| Adlakha, S | 1 |
| Groves, M | 1 |
| Hepburn, M | 1 |
| Kanz, L | 1 |
| Larsen, SR | 1 |
| Manoharan, A | 1 |
| Raza, A | 1 |
| Qawi, H | 1 |
| Lisak, L | 1 |
| Andric, T | 1 |
| Dar, S | 1 |
| Andrews, C | 1 |
| Venugopal, P | 1 |
| Gezer, S | 1 |
| Gregory, S | 1 |
| Loew, J | 1 |
| Robin, E | 1 |
| Rifkin, S | 1 |
| Hsu, WT | 1 |
| Huang, RW | 1 |
| Grossi, A | 2 |
| Fabbri, A | 2 |
| Leoni, F | 1 |
| Nozzoli, C | 1 |
| Longo, G | 1 |
| Pagliai, G | 1 |
| Ciolli, S | 1 |
| Rossi Ferrini, P | 1 |
| Ribizzi, I | 1 |
| Darnowski, JW | 1 |
| Goulette, FA | 1 |
| Sertoli, MR | 1 |
| Calabresi, P | 1 |
| Tefferi, A | 1 |
| Elliott, MA | 1 |
| Steensma, DP | 1 |
| Hook, CC | 1 |
| Dispenzieria, A | 1 |
| Hanson, CA | 1 |
| Schroeder, G | 1 |
| Letendre, L | 1 |
| Yilmaz, A | 1 |
| Kaufmann, CC | 1 |
| Binder, C | 1 |
| Culy, CR | 1 |
| Spencer, CM | 1 |
| Tsiara, SN | 1 |
| Kapsali, HD | 1 |
| Panteli, K | 1 |
| Christou, L | 1 |
| Bourantas, KL | 1 |
| Galanopoulos, A | 2 |
| Kritikou-Griva, E | 2 |
| Gligori, J | 1 |
| Michalis, E | 2 |
| Grigoraki, V | 1 |
| Marinakis, T | 1 |
| Kakkas, J | 1 |
| Tasiopoulou, A | 2 |
| Anagnostopoulos, NI | 2 |
| Neumeister, P | 1 |
| Jaeger, G | 1 |
| Eibl, M | 1 |
| Sormann, S | 1 |
| Zinke, W | 1 |
| Linkesch, W | 1 |
| Musto, P | 1 |
| Balestri, F | 1 |
| Falcone, A | 1 |
| Sanpaolo, G | 1 |
| Viniou, N | 1 |
| Terpos, E | 1 |
| Akel, S | 1 |
| Apostolidou, E | 1 |
| Georgiadou, D | 1 |
| Kouraklis, A | 1 |
| Parharidou, A | 1 |
| Kokkini, G | 1 |
| Symeonidis, A | 1 |
| Christakis, JI | 1 |
| Loukopoulos, D | 1 |
| Yataganas, X | 1 |
| Invernizzi, R | 1 |
| Pecci, A | 1 |
| Travaglino, E | 1 |
| Gobbi, PG | 1 |
| Malabarba, L | 1 |
| Ramajoli, I | 1 |
| Ascari, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study Of Amifostine In Children With Myelodysplastic Syndrome[NCT00098683] | Phase 2 | 10 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Multicenter, Randomized, Double-blind, Phase III Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) With Alteration in 5q- and Anemia Without the Need of Transfusion.[NCT01243476] | Phase 3 | 61 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for amifostine anhydrous and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
[Mechanism and problem of amifostine in treating myelodysplastic syndromes].
Topics: Amifostine; Humans; Myelodysplastic Syndromes; Radiation-Protective Agents | 2009 |
Developmental therapeutics for myelodysplastic syndromes.
Topics: Amifostine; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Enzyme Inhibitor | 2006 |
Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?
Topics: Amifostine; Cell Differentiation; Clinical Trials as Topic; Cytoprotection; Hematopoiesis; Humans; M | 1998 |
Differentiation therapy of myelodysplastic syndromes: fact or fiction?
Topics: Acetamides; Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Argin | 1998 |
Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia.
Topics: Acute Disease; Amifostine; Animals; Apoptosis; Cytoprotection; Hematologic Neoplasms; Hematopoietic | 1999 |
Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Topics: Amifostine; Animals; Cytoprotection; Drug Interactions; Economics, Pharmaceutical; Half-Life; Humans | 2001 |
New approaches to the treatment of myelodysplasia.
Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptos | 2002 |
10 trials available for amifostine anhydrous and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes.
Topics: Aged; Amifostine; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Myelo | 2009 |
A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121).
Topics: Adolescent; Amifostine; Child; Child, Preschool; Female; Humans; Infant; Male; Myelodysplastic Syndr | 2011 |
Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study.
Topics: Adult; Amifostine; Busulfan; Cause of Death; Cytoprotection; Hematopoietic Stem Cell Transplantation | 2003 |
Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.
Topics: Aged; Amifostine; Female; Hematopoiesis; Humans; Injections, Intravenous; Male; Middle Aged; Myelody | 1997 |
Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patients.
Topics: Amifostine; Enzyme-Linked Immunosorbent Assay; Hematopoiesis; Hematopoietic Stem Cells; Humans; Myel | 1998 |
Amifostine in the treatment of low-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Amifostine; Blood Cell Count; Erythropoietin; Female; Humans; Male; Middle | 2000 |
Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes.
Topics: Aged; Amifostine; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Blood Transfusion; | 2001 |
Treatment of patients with myelodysplastic syndrome with amifostine.
Topics: Aged; Aged, 80 and over; Amifostine; Cell Division; Dose-Response Relationship, Drug; Drug Administr | 2001 |
Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Coun | 2001 |
Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
Topics: Aged; Aged, 80 and over; Amifostine; Anemia, Refractory; Bone Marrow Cells; Colony-Forming Units Ass | 2002 |
18 other studies available for amifostine anhydrous and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Successful management of acute myeloid leukemia transformed from myelodysplastic syndromes in an elderly patient aged over 80 years old by ultralow dose decitabine combined with amifostine and autologous CIK cells.
Topics: Aged, 80 and over; Amifostine; Azacitidine; Cells, Cultured; Combined Modality Therapy; Cytokine-Ind | 2014 |
Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Dexamethason | 2008 |
[Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome].
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Computational Biology; Drug Administration Schedule; Dru | 2009 |
Myelodysplastic syndrome in children: changing definitions from FAB 1976 to WHO 2008 classification systems.
Topics: Amifostine; Female; Humans; Male; Myelodysplastic Syndromes; Radiation-Protective Agents | 2011 |
Amifostine does not preferentially stimulate the growth of residual polyclonal progenitor cells in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Anemia, Refractory; Antigens, CD34; Cell Division; Cells | 2003 |
Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Amifostine; Anemia; Anemia, Iron-Deficiency; Drug Therapy, Combination; Ery | 2003 |
[Short-term curative effect of amifostine combined with rhEPO on aged patients wilh myelodysplastic syndrome].
Topics: Aged; Aged, 80 and over; Amifostine; Drug Therapy, Combination; Erythropoietin; Humans; Male; Myelod | 2005 |
Amifostine exerts anti-angiogenic activity and suppresses vascular endothelial growth factor secreted by hemopoietic stem/progenitor cells.
Topics: Amifostine; Case-Control Studies; Cell Proliferation; Cells, Cultured; Enzyme-Linked Immunosorbent A | 2005 |
[Amifostine in treatment of five patients with myelodysplastic syndrome].
Topics: Adult; Aged; Amifostine; Benzene; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 2006 |
[Amifostine used in the treatment of patients with myelodysplastic syndrome].
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Drug Therapy, Combination; Erythropoietin; Female; Human | 2007 |
Amifostine in the treatment of patients with myelodysplastic syndrome.
Topics: Amifostine; Hematopoiesis; Humans; Myelodysplastic Syndromes; Radiation-Protective Agents | 1999 |
Oxidative stress and the myelodysplastic syndromes.
Topics: Amifostine; Apoptosis; Bone Marrow; Humans; Myelodysplastic Syndromes; Oxidative Stress | 2000 |
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Anorexia; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line.
Topics: Amifostine; Apoptosis; Cell Division; Cell Separation; Flow Cytometry; Humans; Immunophenotyping; My | 2000 |
Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome.
Topics: Aged; Amifostine; Drug Therapy, Combination; Erythropoietin; Female; Humans; Male; Middle Aged; Myel | 2001 |
Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome.
Topics: Amifostine; Apoptosis; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Radiation-Protective Ag | 2001 |
Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Amifostine; Drug Evaluation; Drug Therapy, Combination; Erythropoietin; Fem | 2002 |
Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes.
Topics: Aged; Amifostine; Antioxidants; Apoptosis; Bone Marrow Cells; Female; Follow-Up Studies; Humans; Mal | 2002 |